Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids

Goserelin versus leuprolide before hysterectomy for uterine fibroids

“…Uterine volume derived from ultrasound assessment decreased by 25.9% after GnRH agonist treatment in the present study, a reduction broadly in line with that reported by a Cochrane meta‐analysis [12].…”

“…In the present trial the mean rise in hemoglobin levels of 2 g/dL after treatment with 3 doses of either goserelin or leuprolide is comparable with previous trials of preoperative GnRH agonists for fibroids, which have shown hemoglobin changes ranging from 0–2.6 g/dL [12,15,16,18–20]. Routine iron supplementation within our protocol may have optimized the increase.…”

Goserelin versus leuprolide before hysterectomy for uterine fibroids

“…Uterine volume derived from ultrasound assessment decreased by 25.9% after GnRH agonist treatment in the present study, a reduction broadly in line with that reported by a Cochrane meta‐analysis [12].…”

“…In the present trial the mean rise in hemoglobin levels of 2 g/dL after treatment with 3 doses of either goserelin or leuprolide is comparable with previous trials of preoperative GnRH agonists for fibroids, which have shown hemoglobin changes ranging from 0–2.6 g/dL [12,15,16,18–20]. Routine iron supplementation within our protocol may have optimized the increase.…”

CDB-2914 for Uterine Leiomyomata Treatment: A Randomized Controlled Trial

“…A meta-analysis of GnRH agonist use for the treatment of leiomyomata found that the mean difference with PLC treatment women was small (1.0 g/dL; 95% confidence interval 0.7-1.2). 17 Because this falls within the range seen in this study, perhaps with a larger sample size, a similar difference would be detected with CDB-2914 treatment.…”

CDB-2914 for Uterine Leiomyomata Treatment

“…17 Because this falls within the range seen in this study, perhaps with a larger sample size, a similar difference would be detected with CDB-2914 treatment. It is possible that the inclusion criteria requiring a hemoglobin level more than 10 g/dL obscured a potential effect.…”

Goserelin versus leuprolide before hysterectomy for uterine fibroids

“…Uterine volume derived from ultrasound assessment decreased by 25.9% after GnRH agonist treatment in the present study, a reduction broadly in line with that reported by a Cochrane meta‐analysis [12].…”

“…In the present trial the mean rise in hemoglobin levels of 2 g/dL after treatment with 3 doses of either goserelin or leuprolide is comparable with previous trials of preoperative GnRH agonists for fibroids, which have shown hemoglobin changes ranging from 0–2.6 g/dL [12,15,16,18–20]. Routine iron supplementation within our protocol may have optimized the increase.…”

CDB-2914 for Uterine Leiomyomata Treatment: A Randomized Controlled Trial

“…A meta-analysis of GnRH agonist use for the treatment of leiomyomata found that the mean difference with PLC treatment women was small (1.0 g/dL; 95% confidence interval 0.7-1.2). 17 Because this falls within the range seen in this study, perhaps with a larger sample size, a similar difference would be detected with CDB-2914 treatment.…”

CDB-2914 for Uterine Leiomyomata Treatment

“…17 Because this falls within the range seen in this study, perhaps with a larger sample size, a similar difference would be detected with CDB-2914 treatment. It is possible that the inclusion criteria requiring a hemoglobin level more than 10 g/dL obscured a potential effect.…”

Goserelin versus leuprolide before hysterectomy for uterine fibroids

“…Uterine volume derived from ultrasound assessment decreased by 25.9% after GnRH agonist treatment in the present study, a reduction broadly in line with that reported by a Cochrane meta‐analysis [12].…”

“…In the present trial the mean rise in hemoglobin levels of 2 g/dL after treatment with 3 doses of either goserelin or leuprolide is comparable with previous trials of preoperative GnRH agonists for fibroids, which have shown hemoglobin changes ranging from 0–2.6 g/dL [12,15,16,18–20]. Routine iron supplementation within our protocol may have optimized the increase.…”

CDB-2914 for Uterine Leiomyomata Treatment: A Randomized Controlled Trial

“…A meta-analysis of GnRH agonist use for the treatment of leiomyomata found that the mean difference with PLC treatment women was small (1.0 g/dL; 95% confidence interval 0.7-1.2). 17 Because this falls within the range seen in this study, perhaps with a larger sample size, a similar difference would be detected with CDB-2914 treatment.…”

CDB-2914 for Uterine Leiomyomata Treatment

“…17 Because this falls within the range seen in this study, perhaps with a larger sample size, a similar difference would be detected with CDB-2914 treatment. It is possible that the inclusion criteria requiring a hemoglobin level more than 10 g/dL obscured a potential effect.…”